Master Working Cell Bank Supplements

MCB/WCB is the two-tier cryogenic cell-banking system that preserves a defined microbial strain (probiotic, fermentation organism, starter culture) across the multi-year operational life of a manufacturing programme. The Master Cell Bank is the finite, deeply-characterised seed lot derived from the original isolate; the Working Cell Bank is a daughter lot expanded from a single MCB vial and used as the everyday production seed. The system protects against genetic drift (which would invalidate strain-specific claims), provides forensic chain-of-custody for label claims, and protects proprietary strains as trade-secret assets.

• Tier 0 (Research Cell Bank / Isolate) — original isolate from research lab, single-strain pure culture, deposited type strain or de-novo isolate. Typically 1-10 vials.
• Tier 1 (Master Cell Bank — MCB) — single passage expansion from Tier 0; deeply characterised once; typically 100-500 vials stored cryogenically. NEVER used directly for production. MCB is the strategic asset; protected from depletion.
• Tier 2 (Working Cell Bank — WCB) — single passage expansion from a single MCB vial; lightly characterised vs MCB; typically 500-2000 vials. Used as day-to-day production seed; re-generated from MCB every 2-5 years as inventory depletes.
• Tier 3 (Production fermentation) — single passage expansion from a single WCB vial; produces the finished bulk biomass for product manufacture.

Because the MCB is the strategic master, it is characterised once with the deepest possible analytical battery — far more rigorous than any subsequent WCB or production-lot test. Per adapted ICH Q5A/Q5D framework:

• Identity — full genome sequencing (Illumina + Oxford Nanopore long-read for closed assembly); 16S rRNA full-length; biochemical profile (API 50 CHL); phenotypic confirmation against deposited type strain at ATCC / DSMZ / BCCM.
• Purity — single-strain confirmation via 16S sequencing of multiple colonies; absence of contaminating organisms via selective media; absence of bacteriophage.
• Antimicrobial resistance profile — EFSA QPS guidance compliance for probiotic strains; full antibiotic-resistance panel; absence of transferable resistance genes (mob+, mob-, plasmid-borne).
• Virulence factors — absence of known virulence genes via whole-genome sequencing search; absence of toxin genes (e.g. cytolysin, enterotoxin).
• Stability — viability after extended cryogenic storage (initial + 5-year + 10-year time points); genetic stability over passage (whole-genome resequencing of passage-20 vs MCB).
• Strain-specific properties — for probiotics, adherence to intestinal cells (Caco-2 model), bile-salt tolerance, acid tolerance, antimicrobial activity, immunomodulatory profile.
• Cryopreservation — freeze-thaw recovery rate; cryoprotectant formulation (typically glycerol 15-20% or trehalose 10-15%); fill volume; vial closure verification.
• Stored aliquots — multiple vials retained at -80°C primary location + duplicate location (geographically separated, different power grid, different building).

When current WCB inventory falls below threshold (typically 6-12 months consumption), a new WCB is generated:

• Single MCB vial thawed; aseptic transfer to fresh growth medium; single-passage expansion in defined conditions.
• Cell density quantified at harvest (typically 10^9-10^10 CFU/mL).
• Aliquoted into multiple cryovials (typically 500-2000 vials of 1-2 mL each) with cryoprotectant.
• Snap-frozen and transferred to long-term storage.
• Lighter characterisation than MCB but still substantial: full-length 16S identity, viability recovery rate, single-strain confirmation, antibiotic-resistance check, freeze-thaw stability.
• WCB lot release tested and approved before any production use; chain of custody linked back to MCB vial of origin.

• Storage temperature — -80°C ultra-low-temperature freezer (most common) or liquid nitrogen vapour-phase dewar (-196°C, for highest-stability requirements). LN2 storage extends MCB shelf life from 10-20 years (-80°C) to multi-decade (-196°C).
• Redundant storage — primary + backup location, geographically separated, different power grid, different building. Many premium operations use third-party cryogenic-storage vendors for backup.
• Power redundancy — UPS + generator backup at both locations. Continuous temperature monitoring + 24/7 alert escalation. Backup freezer available in same location for emergency transfer.
• Access control — biometric or two-factor access; vial-pull log; chain of custody from vial removal through use.
• Vial inventory — barcoded vials with location tracking (rack / row / position); inventory levels tracked in LIMS or QMS; auto-alert when below threshold.
• Cryogenic-glove + face-shield + apron PPE for vial handling; LN2 burn / cold-injury training for personnel.

• Single-tier banking — production seeded directly from MCB (no WCB tier). Depletes MCB rapidly; strategic asset lost.
• WCB regenerated from WCB — second-generation WCB seeded from prior WCB vial instead of from MCB. Compounds genetic drift; defeats the purpose of MCB tier.
• No backup storage — single freezer location; freezer failure or facility fire destroys irreplaceable seed stock. Most catastrophic single-point failure in probiotic manufacturing.
• Cryoprotectant variation — different cryoprotectant formulation between MCB and WCB; viability recovery rates differ; production-lot CFU yield variable.
• Insufficient characterisation depth — MCB characterised at WCB level (lighter battery); strain identity for premium claims (clinical strain, patented strain) not defensible.
• Vial inventory not tracked — pulls not logged; chain of custody from vial removal to production batch lost.
• WCB used past stability window — viability recovery rate drops below threshold over years of storage; production-lot CFU yield drops; brand experiences declining release potency.
• Antibiotic-resistance gene drift — whole-genome resequencing of WCB shows acquired transferable resistance gene not present in MCB; EFSA QPS status revoked; market access blocked.
• Vendor cell-bank reliance — brand relies on supplier-provided cell bank; supplier bankruptcy or business change disrupts brand's continuity of supply.

• Strain master register: per-strain entry with genus + species + strain designation + deposit reference (ATCC / DSMZ / BCCM) + WGS file reference + EFSA QPS status.
• Cell-bank lot register: per-MCB lot + per-WCB lot record with derivation date, source vial (for WCB → MCB linkage), characterisation evidence reference, cryoprotectant formulation, vial count at creation, current vial inventory.
• Vial inventory: per-vial barcoded record with location (freezer / rack / row / position), pull history, in-use status; pulls logged with date + operator + purpose.
• WCB-from-MCB enforcement: workflow blocks WCB generation if source vial is anything other than MCB; second-generation WCB explicitly prohibited at workflow level.
• Inventory-threshold alerts: per-WCB inventory auto-alert at configurable thresholds (12 / 6 / 3 months remaining at current consumption); triggers WCB-regeneration workflow.
• Production-batch linkage: each production fermentation batch records the WCB vial of origin; full chain of custody from production batch back to WCB lot back to MCB lot back to original isolate.
• Storage-location redundancy: per-cell-bank flag for primary + backup storage locations; alert if only one location populated.
• Temperature-monitoring integration: cryogenic-storage temperature monitoring integrated; out-of-spec events log + recovery + impact-assessment workflow.
• Characterisation evidence pack: per-MCB + per-WCB one-click export of full characterisation pack (WGS report, identity confirmation, antibiotic-resistance profile, virulence-gene absence, viability recovery, cryopreservation validation) for FDA inspection / brand audit / customer due-diligence.
• Trade-secret protection: per-strain access-control matrix; sensitive strain data (WGS, isolation history, fermentation conditions) visible only to authorised users; supplier portal exposes only the non-sensitive identity confirmation.